|
Epigenetic activity of normal and cancer-associated mutant H1 linker histones
|
5F30CA210539-03
|
$44,524
|
HEALTON, SEAN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Enhanced Training and Mentorship of Hematologic Oncologists
|
2R25CA168526-06
|
$306,150
|
SUNG, LILLIAN
|
AMERICAN SOCIETY OF HEMATOLOGY
|
|
Chemotherapy-induced MDSCs and antitumor immunity
|
5R01CA215523-02
|
$347,700
|
ZHOU, GANG
|
AUGUSTA UNIVERSITY
|
|
SPORE in Lymphoma
|
5P50CA126752-12
|
$2,297,796
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
City of Hope Lymphoma SPORE
|
2P50CA107399-11A1
|
$2,500,000
|
FORMAN, STEPHEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
CD25-mediated feedback control of BCR-signaling and its oncogenic mimics
|
5R01CA213138-02
|
$395,738
|
MUSCHEN, MARKUS
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Precision Antibody-Based Therapy to Neutralize Epstein-Barr Virus-Associated PTLDs
|
1R21CA232275-01
|
$225,765
|
OGEMBO, JAVIER
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
A novel VLP vaccine to prevent EBV infection and EBV - associated malignancies
|
3R21CA205106-02S1
|
$77,331
|
OGEMBO, JAVIER
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
A novel VLP vaccine to prevent EBV infection and EBV - associated malignancies
|
5R21CA205106-02
|
$176,605
|
OGEMBO, JAVIER
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
2P30CA033572-35
|
$2,543,187
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-34S3
|
$865,000
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-35S1
|
$43,750
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Risk factors for molecular subtypes of NHL a prospective evaluation
|
5R01CA202712-03
|
$668,277
|
WANG, SOPHIA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Mechanisms of resistance to ALK inhibitors in ALK-rearranged lymphoma
|
5R01CA196703-04
|
$404,888
|
CHIARLE, ROBERTO
|
BOSTON CHILDREN'S HOSPITAL
|
|
A Follow-up Study for Causes of Cancer in Black Women
|
5U01CA164974-08
|
$3,131,894
|
ROSENBERG, LYNN
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-05S1
|
$3,249,644
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-05S2
|
$1,000,000
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
5U10CA180821-05
|
$8,073,787
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Transforming the diagnosis and care of patients with CTCL using TCR sequencing
|
5R01CA203721-03
|
$679,022
|
CLARK, RACHAEL
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Epstein-Barr Virus Nuclear Protein B Cell Growth Transformation
|
5R01CA047006-31
|
$532,500
|
ZHAO, BO
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
CAR-T cell control through orthogonal antibody-based switches
|
5R01CA208398-03
|
$412,234
|
YOUNG, TRAVIS
|
CALIFORNIA INSTITUTE/BIOMEDICAL RESEARCH
|
|
Case Comprehensive Cancer Center Support Grant
|
2P30CA043703-28
|
$5,637,954
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-28S1
|
$249,965
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Contribution of Gynecologic and Breast Cancer Biospecimens from African American women to HCMI
|
3P30CA043703-28S2
|
$48,000
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
5U10CA180853-05
|
$1,187,291
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
A Phase I trial combining IV fenretinide and IV safingol to target overproduction
|
5R44CA183316-03
|
$473,425
|
SIMPSON, WILLIAM
|
CERRX, INC.
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-05S1
|
$2,256,906
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
5U10CA180886-05
|
$20,853,800
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
MYC as a Biomarker in Aggressive Non-Hodgkin Lymphoma
|
5R01CA187415-04
|
$457,439
|
LI, YONG
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Roles and Regulation of wild-type and mutant forms of p53
|
5P01CA087497-17
|
$1,885,586
|
PRIVES, CAROL
|
COLUMBIA UNIV NEW YORK MORNINGSIDE
|
|
Defining the functions and translational potential of ferroptosis
|
5R35CA209896-03
|
$955,184
|
STOCKWELL, BRENT
|
COLUMBIA UNIV NEW YORK MORNINGSIDE
|
|
Development of first-in-class histone acetyltransferase (HAT) activators for precision targeting of epigenetic derangements in lymphoma
|
1R01CA222931-01A1
|
$370,575
|
AMENGUAL, JENNIFER
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
From pathogenesis to new therapeutic targets in Diffuse Large B cell Lymphoma
|
5R35CA210105-03
|
$960,000
|
DALLA-FAVERA, RICCARDO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
DNA double-strand break repair, chromosomes translocations and cancer
|
5P01CA174653-05
|
$1,778,566
|
GAUTIER, JEAN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Regulation of p53 acetylation and deacetylation in tumorigenesis
|
5R01CA085533-15
|
$288,000
|
GU, WEI
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Regulation of SLC7A11 by p53 in cancer metabolism
|
5R01CA190477-03
|
$366,000
|
GU, WEI
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
HAUSP inhibitors in p53-wild type and p53-mutant tumors
|
5R01CA193890-04
|
$366,000
|
GU, WEI
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Mechanisms of targeting oncoprotein SET in tumor suppression
|
5R01CA216884-02
|
$366,000
|
GU, WEI
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The role of a novel fusion oncogene FYN-TRAF3IP2 in peripheral T-cell lymphoma
|
1F30CA225052-01
|
$41,983
|
KIM, CHRISTINE
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The role of RHOA G17V mutation in peripheral t-cell lymphomas
|
5R01CA197945-04
|
$366,000
|
PALOMERO, TERESA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Role of KMT2D Gene Inactivation in B cell Non Hodgkin Lymphoma
|
2R01CA172492-06A1
|
$384,750
|
PASQUALUCCI, LAURA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-44S1
|
$120,000
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-44S2
|
$60,000
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant - PDXNet Supplement
|
3P30CA013696-44S3
|
$126,563
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-44S4
|
$191,726
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-44S5
|
$237,191
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-44S6
|
$246,815
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-44S7
|
$224,982
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-44S8
|
$126,563
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-44S9
|
$250,000
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|